|
Synonyms: example 5 [US10889571B2] | HS-10382 | TERN-701
Compound class:
Synthetic organic
Comment: This compound is an allosteric ABL kinase inhibitor that was developed for antineoplastic activity in BCR::ABL1 fusion positive myeloma [2]. It binds the ABL myristoyl pocket. The chemical structure was obtained from WHO proposed list 134 (Feb 2026), and matched to an example in patent US10889571B2. Predicted to be Terns Pharmaceuticals' allosteric
BCR-ABL inhibitor TERN-701.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| Bioactivity Comments |
| Retains activity against the ABL1 T315I gatekeeper mutation (IC50 3.8 nM), and active-site and A-loop mutations (IC50 values 0.3-2.1 nM) [1]. |
| Selectivity at enzymes | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||